Skip to content

Efficacy of high-frequency repetitive transcranial magnetic stimulation combined with dialectical behavioral therapy in adolescents with depressive disorder with non-suicidal self-injury

Efficacy of high-frequency repetitive transcranial magnetic stimulation combined with dialectical behavioral therapy in adolescents with depressive disorder with non-suicidal self-injury

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105395
Enrollment
Unknown
Registered
2025-07-02
Start date
2023-06-30
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive disorder

Interventions

Active treatment group:Active rTMS combined with DBT-A
Sham treatment group:Sham rTMS combined with DBT-A

Sponsors

Shanghai Mental Health Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1. Age>=13 years and 13; 4. Meet the DSM-5 diagnostic criteria for depressive disorders; 5. The number of self-injuries is greater than 5 times within 12 months, and there are thoughts of self-harm in the past month; 6. Agree to participate in the study, and the adolescent and parents sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Consistent with DSM-5 pervasive developmental disorder, psychotic disorder, bipolar disorder, borderline personality disorder, attention deficit hyperactivity disorder, and history of severe cerebral organic disease, epilepsy or other major neurological disorders; 2. History of mild to severe drug use disorder within the last 3 months; 3. Have a history of failed brain stimulation (rTMS, electroconvulsive therapy, or transcranial electrical stimulation) in the past or are undergoing electroconvulsive therapy; 4. The head has any type of non-removable metal or other metal device or object implanted in or near the head; cardiac pacemakers, etc.; 5. The use of benzodiazepines, bupropion, valproate drugs that significantly affect the stimulation threshold; 6. Use of antidepressants or high doses of antipsychotic drugs in excess of the dose, such as sertraline > 200 mg/day, escitalopram > 20 mg/day, fluoxetine > 60 mg/day, fluvoxamine > 300 mg/day, risperidone > 2 mg/day, olanzapine > 10 mg/day, quetiapine greater than 400 mg/day, aripiprazole > 20 mg/day.

Design outcomes

Primary

MeasureTime frame
Beck Depression Self-Rating Scale score;Ottawa Self-Injury Questionnaire Score;

Secondary

MeasureTime frame
Childhood depressive disorder self-rating scale score;Anxiety Mood Disorder Screening Form score in children;Simplified Coping Style Questionnaire;N-back task;Emotional stroop task;Stop-signal task;Hamilton Depression Rating Scale score;

Countries

China

Contacts

Public ContactWenhong Cheng

Shanghai Mental Health Center

chengwhb@aliyun.com+86 21 3477 3080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026